Paloma Partners’s VolitionRx Ltd VNRX Stock Holding History

Paloma Partners’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,695	Closed	-$128K	–	2313
2021 Q1	$128K	Buy	+1,695	New	+$145K	﹤0.01%	1881

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paloma Partners's VNRX Position: Q2 2021 in Review

Paloma Partners sold out of VolitionRx Ltd (VNRX) in Q2 2021, closing a stake of 1,695 shares — an estimated $128K sold.

Paloma Partners first reported a position in VNRX in Q1 2021 and held it in 1 quarter. The position peaked at $128K in Q1 2021. 46 funds tracked by Wall St. Rank hold VNRX as of Q2 2021.

Paloma Partners reported no remaining VolitionRx Ltd position as of Q2 2021 after selling out during the quarter.
Paloma Partners sold 1,695 VolitionRx Ltd shares in Q2 2021, an estimated $128K.
Paloma Partners first reported a position in VolitionRx Ltd in Q1 2021 and held it in 1 quarter.
Paloma Partners's VolitionRx Ltd position peaked at $128K in Q1 2021.
46 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2021.

Based on Paloma Partners's 13F filing for Q2 2021, filed 16 Aug 2021.